BR9506292A - Composto e seus sais fisiologicamente aceitáveis processo para a preparaçÃo do mesmo e composiçÃo farmacêutica - Google Patents

Composto e seus sais fisiologicamente aceitáveis processo para a preparaçÃo do mesmo e composiçÃo farmacêutica

Info

Publication number
BR9506292A
BR9506292A BR9506292A BR9506292A BR9506292A BR 9506292 A BR9506292 A BR 9506292A BR 9506292 A BR9506292 A BR 9506292A BR 9506292 A BR9506292 A BR 9506292A BR 9506292 A BR9506292 A BR 9506292A
Authority
BR
Brazil
Prior art keywords
compound
acceptable salts
physiologically acceptable
formulaused
motoricity
Prior art date
Application number
BR9506292A
Other languages
English (en)
Inventor
Ramon Merce-Vidal
Jordi Frigola-Constansa
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of BR9506292A publication Critical patent/BR9506292A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D521/00Heterocyclic compounds containing unspecified hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
BR9506292A 1994-07-29 1995-07-26 Composto e seus sais fisiologicamente aceitáveis processo para a preparaçÃo do mesmo e composiçÃo farmacêutica BR9506292A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9409443A FR2723091B1 (fr) 1994-07-29 1994-07-29 Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles
PCT/EP1995/002978 WO1996004287A1 (fr) 1994-07-29 1995-07-26 Tetrahydropyridine-(ou 4-hydroxypiperidine) alkylazoles ayant une activite pour les recepteurs sigma et/ou 5ht1a

Publications (1)

Publication Number Publication Date
BR9506292A true BR9506292A (pt) 1997-08-12

Family

ID=9465902

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9506292A BR9506292A (pt) 1994-07-29 1995-07-26 Composto e seus sais fisiologicamente aceitáveis processo para a preparaçÃo do mesmo e composiçÃo farmacêutica

Country Status (22)

Country Link
US (2) US5731331A (pt)
EP (1) EP0721455B9 (pt)
JP (2) JP4035787B2 (pt)
KR (1) KR100389785B1 (pt)
CN (1) CN1120167C (pt)
AT (1) ATE229530T1 (pt)
AU (1) AU712479B2 (pt)
BR (1) BR9506292A (pt)
CA (1) CA2172986A1 (pt)
CZ (1) CZ293123B6 (pt)
DE (1) DE69529142T2 (pt)
DK (1) DK0721455T3 (pt)
FI (1) FI116386B (pt)
FR (1) FR2723091B1 (pt)
HU (1) HU220088B (pt)
NO (1) NO309379B1 (pt)
NZ (1) NZ291172A (pt)
PL (1) PL183766B1 (pt)
PT (1) PT721455E (pt)
RU (1) RU2168507C2 (pt)
WO (1) WO1996004287A1 (pt)
ZA (1) ZA956314B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2723091B1 (fr) * 1994-07-29 1996-11-08 Esteve Labor Dr Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles
FR2742052B1 (fr) * 1995-12-12 1998-04-10 Esteve Labor Dr Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports
GB9613423D0 (en) * 1996-06-26 1996-08-28 Lilly Industries Ltd Pharmaceutical compounds
HUP9602763A3 (en) * 1996-10-09 1999-05-28 Egyt Gyogyszervegyeszeti Gyar 3-phenyl isoxazole derivatives, process for producing them and pharmaceutical compositions containing the same
US5919802A (en) * 1997-12-05 1999-07-06 Princeton University Methods of preventing and/or treating temporal lobe epilepsy
ES2151828B1 (es) * 1998-07-10 2001-08-16 Esteve Labor Dr Empleo de derivados de tetrahidropiridinas (ohidroxi-piperidinas)-b utilazoles en la elaboracion de un medicamento para el tratamiento del dolor.
US6046331A (en) * 1998-12-17 2000-04-04 Synaptic Pharmaceutical Corporation Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
DE10109867A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE10109866A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
EP1634873A1 (en) * 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
ES2251317B1 (es) * 2004-10-14 2007-03-16 Laboratorios Del Dr. Esteve, S.A. Inhibidores del receptor sigma.
ES2251316B1 (es) * 2004-10-14 2007-03-16 Laboratorios Del Dr. Esteve, S.A. Inhibidores del receptor sigma.
BRPI0514736A (pt) 2004-08-27 2008-06-24 Esteve Labor Dr inibidores do receptor sigma
KR100893394B1 (ko) * 2007-05-11 2009-04-17 한국화학연구원 아릴 피페리딘기-함유 이미다졸 유도체, 이의 제조방법 및이를 유효성분으로 포함하는 약학적 조성물
US8198307B2 (en) * 2007-05-11 2012-06-12 Korea Research Institute Of Chemical Technology Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same
KR100895998B1 (ko) * 2007-05-11 2009-05-07 한국화학연구원 아릴 피페리딘기-함유 이미다졸 유도체, 이의 제조방법 및이를 유효성분으로 포함하는 약학적 조성물
KR100871077B1 (ko) * 2007-05-11 2008-11-28 한국화학연구원 아릴 피페리딘기-함유 이미다졸 유도체, 이의 제조방법 및이를 유효성분으로 포함하는 약학적 조성물
BR122021013836B1 (pt) 2009-12-04 2022-05-24 Sunovion Pharmaceuticals, Inc. Composto e seu uso, composição farmacêutica
JP2019523279A (ja) 2016-07-29 2019-08-22 サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. 化合物および組成物ならびにそれらの使用
MX2019000980A (es) 2016-07-29 2019-07-04 Sunovion Pharmaceuticals Inc Compuestos y composiciones y usos de los mismos.
JP7146782B2 (ja) 2017-02-16 2022-10-04 サノビオン ファーマシューティカルズ インク 統合失調症を処置する方法
CN109280030B (zh) * 2017-07-19 2022-04-22 江苏恩华药业股份有限公司 苯骈氮杂烷基芳基哌嗪衍生物及在制备药物中的应用
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
CN118406063A (zh) 2018-02-16 2024-07-30 赛诺维信制药公司 盐、晶型及其制备方法
US11136304B2 (en) 2019-03-14 2021-10-05 Sunovion Pharmaceuticals Inc. Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
MX2022012833A (es) 2020-04-14 2022-11-07 Sunovion Pharmaceuticals Inc (s)-(4,5-dihidro-7h-tieno[2,3-c]piran-7-il)-n-metilmetanamina para tratar trastornos neurologicos y psiquiatricos.

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509153A (en) * 1967-03-24 1970-04-28 Miles Lab 5-phenyl (or 5-phenylalkyl)-2-(omega-(4-phenyl-1-piperazinyl)alkyl)tetrazoles
US3635982A (en) * 1969-04-08 1972-01-18 American Home Prod Amino-substituted-quinoxalinyloxazolidines and -oxazines
ES378315A1 (es) * 1969-04-11 1972-06-01 Robins Co Inc A H Un procedimiento para la preparacion de 1 - (omega-susti- tuido-alcohil)-2-metilbenzimidazoles.
JPS5011395B1 (pt) * 1970-12-29 1975-04-30
NZ181256A (en) * 1975-07-21 1978-04-28 Janssen Pharmaceutica Nv 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives
US3981881A (en) * 1975-08-14 1976-09-21 E. R. Squibb & Sons, Inc. 2-[(4-Phenyl-tetrahydropyridinyl)alkyl]-1H-isoindole-1,3(2H)-diones
US3994904A (en) * 1976-03-08 1976-11-30 Miles Laboratories, Inc. 3-Substituted -5-phenyl-5-pyridyl hydantoins
JPS5746983A (en) * 1980-09-04 1982-03-17 Eisai Co Ltd Theophylline derivative and its preparation
JPS58150511A (ja) * 1982-03-02 1983-09-07 Eisai Co Ltd テオフイリン誘導体を有効成分とする脳循環代謝改善剤
DE3364234D1 (en) * 1982-03-02 1986-07-31 Eisai Co Ltd Antiphlogistic/antipyretic/analgesic pharmaceutical compositions containing theophylline derivatives as active ingredient
US4539407A (en) * 1983-12-13 1985-09-03 American Home Products Corporation β-Carboline anticonvulsants
US4675403A (en) * 1985-10-16 1987-06-23 American Home Products Corporation 3-Aminoalkyl derivatives of 5,5-disubstituted hydantoins with psychotropic activity
US4754038A (en) * 1987-02-26 1988-06-28 American Home Products Corporation Carboline histamine H1 antagonists
DE69021855T2 (de) * 1990-01-02 1996-02-29 Fujisawa Pharmaceutical Co Quinazolinderivate und ihre Herstellung.
US5296487A (en) * 1990-01-02 1994-03-22 Fujisawa Pharmaceutical Co., Ltd. Quinazoline derivatives and their preparation
FR2672052B1 (fr) * 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
JP3198117B2 (ja) * 1990-02-07 2001-08-13 サントリー株式会社 ピロロアゼピン誘導体
US5149817A (en) * 1990-03-05 1992-09-22 Shionogi & Co., Ltd. Teirahydropyridine derivatives
JPH04211059A (ja) * 1990-03-05 1992-08-03 Shionogi & Co Ltd 新規なテトラヒドロピリジン誘導体
FR2671972B1 (fr) * 1991-01-25 1995-03-03 Esteve Labor Dr Utilisation de derives 1-h-azole-(omega-(4-(2-pyrimidinyl)-1-piperazinyl)-alkyl) pour la preparation de medicaments destines au traitement des troubles des fonctions cognitives.
FR2673628B1 (fr) * 1991-03-07 1993-07-09 Esteve Labor Dr Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles.
JP3219281B2 (ja) * 1991-04-03 2001-10-15 聰 竹尾 心筋保護剤
DK148392D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
WO1995003298A1 (en) * 1993-07-19 1995-02-02 Fujisawa Pharmaceutical Co., Ltd. BENZIMIDAZOLE DERIVATIVES USEFUL AS DOPAMINE RECEPTOR ANTAGONIST, 5-HT RECEPTOR AGONIST OR α1 RECEPTOR ANTAGONIST
US5411960A (en) * 1993-12-09 1995-05-02 Bayer Aktiengesellschaft Substituted pyrroloanthracenes and -diones
FR2723091B1 (fr) * 1994-07-29 1996-11-08 Esteve Labor Dr Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles

Also Published As

Publication number Publication date
US6232329B1 (en) 2001-05-15
CA2172986A1 (fr) 1996-02-15
WO1996004287A1 (fr) 1996-02-15
FR2723091A1 (fr) 1996-02-02
JP4035787B2 (ja) 2008-01-23
CN1166173A (zh) 1997-11-26
AU712479B2 (en) 1999-11-11
ATE229530T1 (de) 2002-12-15
JPH09503230A (ja) 1997-03-31
DK0721455T3 (da) 2003-04-07
FI961412A (fi) 1996-03-28
CZ92696A3 (en) 1996-09-11
RU2168507C2 (ru) 2001-06-10
US5731331A (en) 1998-03-24
JP2007051154A (ja) 2007-03-01
DE69529142D1 (de) 2003-01-23
HU220088B (hu) 2001-10-28
NZ291172A (en) 1998-02-26
HUT75645A (en) 1997-05-28
PT721455E (pt) 2003-04-30
CZ293123B6 (cs) 2004-02-18
NO309379B1 (no) 2001-01-22
PL313716A1 (en) 1996-07-22
NO961207L (no) 1996-05-29
KR100389785B1 (ko) 2003-10-04
FI961412A0 (fi) 1996-03-28
AU3222595A (en) 1996-03-04
EP0721455A1 (fr) 1996-07-17
KR960704900A (ko) 1996-10-09
HU9600815D0 (en) 1996-07-29
FR2723091B1 (fr) 1996-11-08
EP0721455B1 (fr) 2002-12-11
CN1120167C (zh) 2003-09-03
FI116386B (fi) 2005-11-15
ZA956314B (en) 1996-03-25
EP0721455B9 (fr) 2005-04-20
MX9601191A (es) 1997-12-31
NO961207D0 (no) 1996-03-25
DE69529142T2 (de) 2003-09-25
PL183766B1 (pl) 2002-07-31

Similar Documents

Publication Publication Date Title
BR9506292A (pt) Composto e seus sais fisiologicamente aceitáveis processo para a preparaçÃo do mesmo e composiçÃo farmacêutica
PT96871A (pt) Processo para a preparacao de compostos 3-arilcarbonil-1h-indol uteis como agentes terapeuticos
BR9901491A (pt) 7-hetero-biciclo [2.2.1] - heptanos.
BR0317483A (pt) Derivados de benzodiazepina para o tratamento de desordens neurológicas
FI20115753A (fi) Farmaseuttisia koostumuksia IL-6:n tuoton aiheuttamien sairauksien hoitoon
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
BR0108610A (pt) Compostos azapolicìclicos condensados com arila
CA2501799A1 (en) Pyrazole compounds for treatment of neurodegenerative disorders
DK0687177T3 (da) Anvendelse af lamotrigin ved fremstilling af lægemidler til behandling af AIDS-relaterede nervesygdomme
DE69818678D1 (de) (+)-norcisapride verwendbar bei 5-ht3 und 5-ht4 bedingten krankheiten
BR0013311A (pt) Derivados substituìdos de 1,5-dihidropirrol-2-ona eficazes como antagonistas de receptores nmda para o tratamento de estados de dor
ATE325610T1 (de) Xanthinderivative zur behandlung von hirnischämie
FI954614A0 (fi) Imidatsolokinoksalinonijohdannaiset EAA-antagonisteina
PT768083E (pt) Sertralina para o tratamento de doentes pos-enfarte miocardico
DK1000067T3 (da) Thiazolobenzoheterocycliske forbindelser, deres fremstilling og lægemidler indeholdende forbindelserne
PL376368A1 (en) 4-aminopiperidine derivatives, processes for their preparation and their use as medicaments
BR0316392A (pt) Processo para preparar ácido indan-1,3-dicarboxìlico
TNSN99158A1 (ar) طريقة لمنع الاصابة بالربو
ES2140544T3 (es) Utilizacion de efaroxan y de sus derivados para la fabricacion de medicamentos destinados al tratamiento de las enfermedades neurodegenerativas.
DK0950053T3 (da) Hidtil ukendte benzoylalkyl.1,2,3,6-tetrahydropyridinderivater
MX9704621A (es) Amidas de acido 4-amino-2-ureido-pirimidin-5-carboxilico, procedimientos para su preparacion, medicamentos que contienen estos compuestos, y su utilizacion.
RO81362B1 (ro) Procedeu de obtinere a clorhidratului de vibramicina

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
FF Decision: intention to grant
FG9A Patent or certificate of addition granted
B24C Patent annual fee: request for for restoration

Free format text: REFERENTE 13A., 14A., E 15A. ANUIDADES.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: EXTINGUE-SE A PATENTE EM VIRTUDE DO DISPOSTO NO ART. 78, INCISO IV, DA LPI 9.279, REFERENTE AO DESPACHO PUBLICADO NA RPI 2053 DE 11/05/2010 E AO NAO RECOLHIMENTO DA 16A, 17A E 18A ANUIDADES.